



The Role of Microglia in Human Diseases

Guest Editor:

Dr. Ana Borrajo

Faculty of Pharmacy,
Complutense University of
Madrid, Madrid, Spain

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editor

Dear Colleagues,

Microglia are the primary immune cells of the central nervous system (CNS), similar to peripheral macrophages. They produce a strong proliferative response (microgliosis) to pathogens by changing morphology and migrating to the site of infection, where they destroy pathogens and remove damaged cells. It would be very important to study microglia's involvement in promoting or limiting the pathogenesis of different neuronal diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, multiple sclerosis, X-linked adrenoleukodystrophy (X-ALD), lysosomal storage diseases (LSDs), etc.

In this Special Issue, we invite manuscripts on the role of microglia in different CNS diseases, other infectious diseases such as HIV-1 and HAND, and additional microglial involvement in the pathogenesis of diverse diseases and therapy-based research studies/reviews.

Dr. Ana Borrajo

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)